AC Immune SA
Close on Oct 19, 2026
Earnings
Quarterly results announced on Form 8-K, Item 2.02
| Quarter | Reported | Time | Revenue | EPS (GAAP) | EPS (adjusted) |
|---|---|---|---|---|---|
| Q4 FY2025 Ended Dec 31, 2025 | Mar 13, 2026 | Before market open | – | – | – |
| Q2 FY2025 Ended Jun 30, 2025 | Aug 5, 2025 | Before market open | $1.30M | $-0.21 | – |
| Q4 FY2024 Ended Dec 31, 2024 | Mar 13, 2025 | Before market open | – | – | – |
| Q2 FY2024 Ended Jun 30, 2024 | Aug 6, 2024 | Before market open | – | – | – |
| Q4 FY2023 Ended Dec 31, 2023 | Mar 14, 2024 | Before market open | – | – | – |
| Q2 FY2023 Ended Jun 30, 2023 | Aug 4, 2023 | Before market open | – | $-0.20 | – |
| Q4 FY2022 Ended Dec 31, 2022 | Apr 28, 2023 | Before market open | – | $-0.21 | – |
| Q3 FY2022 Ended Sep 30, 2022 | Oct 28, 2022 | Before market open | – | – | – |
| Q2 FY2022 Ended Jun 30, 2022 | Jul 28, 2022 | Before market open | – | – | – |
| Q4 FY2021 Ended Dec 31, 2021 | Mar 22, 2022 | Before market open | – | – | – |
| Q3 FY2021 Ended Sep 30, 2021 | Nov 8, 2021 | Before market open | – | – | – |
Company guidance
Outlook given with results on Mar 13, 2026, compared with the previous outlook
| Measure | Period | Guidance | vs. prior |
|---|---|---|---|
| total cash expenditurenon-GAAP | full year 2026 | 55 to 65 | New |
Figures and the sentence they come from are taken from the company's earnings release. Hover a measure to read the source sentence.
Press releases
Announcements AC Immune filed with the SEC
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Condensed Consolidated Balance Sheets (Unaudited)
EX-99.1 to Form 6-K
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
EX-99.2 to Form 6-K
AC Immune First Half 2026 Financial and Corporate Update
EX-99.3 to Form 6-K
AC Immune Reports Interim 12-Month Data from
EX-99.1 to Form 6-K
1. AC Immune’s approach to neurodegenerative diseases
EX-99.1 to Form 6-K
AC Immune to Receive Research Grant from Goradia
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Immune Announces Retirement of CEO Dr Andrea Pfeifer at Upcoming AGM
EX-99.1 to Form 6-K
AC Immune First Quarter 2026 Financial and Corporate Updates
EX-99.1 to Form 6-K
AC Immune Initiates Final Cohort in Ongoing Phase
EX-99.1 to Form 6-K
AC Immune Announces Amendment to Morphomer
EX-99.1 to Form 6-K
INDEX TO CONSOLIDATED FINANCIAL STATEMENTS
EX-99.2 to Form 6-K
Statutory Financial Statements (Swiss CO)
EX-99.3 to Form 6-K
AC Immune Initiates Phase 1 Clinical Trial of
EX-99.1 to Form 6-K
AC Immune Positive Interim Phase 2 Data on ACI-7104.056
EX-99.1 to Form 6-K
Condensed Consolidated Balance Sheets (Unaudited)
EX-99.1 to Form 6-K
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
EX-99.2 to Form 6-K
AC Immune Sharpens Pipeline Focus with Operational
EX-99.1 to Form 6-K
Condensed Consolidated Balance Sheets (Unaudited)
EX-99.1 to Form 6-K
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
EX-99.2 to Form 6-K
1. AC Immune’s approach to neurodegenerative diseases
EX-99.1 to Form 6-K
EX-99.2 to Form 6-K
EX-99.2 to Form 6-K
EX-99.3 to Form 6-K
EX-99.3 to Form 6-K
Condensed Consolidated Balance Sheets (Unaudited)
EX-99.1 to Form 6-K
MANAGEMENT’S DISCUSSION AND ANALYSIS OF FINANCIAL CONDITION
EX-99.2 to Form 6-K
AC Immune Reports First Quarter 2025 Financial Results and
EX-99.3 to Form 6-K
Full Year 2024 Financial Results and Provides a Corporate Update
EX-99.1 to Form 6-K
AC Immune Reports Interim Safety Data from Phase
EX-99.1 to Form 6-K